Morgan Stanley thinks Intuitive Surgical’s (ISRG) Q1 report and detailed commentary on tariffs “represents a clearing event for the stock” and sees a “strong entry point to one of the best business models in MedTech.” Outside of tariffs, the base business is “in a strong place,” with procedures up 17% and utilization up 160 basis points year-over-year, adds the analyst, who has an Overweight rating and $650 price target on Intuitive shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical price target lowered to $590 from $605 at Truist
- Intuitive Surgical price target lowered to $575 from $670 at Piper Sandler
- Intuitive Surgical price target lowered to $575 from $600 at Baird
- Intuitive Surgical: Strong Performance and Growth Potential Amidst Challenges
- Intuitive Surgical Reports Strong Q1 2025 Earnings